Search results
Results from the WOW.Com Content Network
New antidepressants, like esketamine and brexanolone, have a fresh approach to treating depression and offer options when other medications may not work. Serotonin reuptake inhibitors...
The FDA has approved Auvelity, a new antidepressant that may treat symptoms faster than other medications. The drug may be especially effective for individuals with treatment-resistant depression. Auvelity joins ketamine as a potential new wave of faster-acting antidepressants.
In 2019, the Food and Drug Administration (FDA) approved two new antidepressants, brexanolone and esketamine. There’s also been renewed interest in agomelatine, an antidepressant not...
The discovery of ketamine has been a game changer for people with severe depression, who often need rapid relief from life-threatening symptoms. Whereas most antidepressants take weeks or months to work, ketamine works within hours to strongly reduce depression symptoms in people for whom other treatments have not worked.
The U.S. Food and Drug Administration on August 19 approved dextromethorphan-bupropion, or Auvelity, a drug used to treat major depressive disorder, also known as clinical depression, in...
The Food and Drug Administration (FDA) in August approved Auvelity—an extended-release dextromethorphan/bupropion tablet—for the treatment of major depressive disorder in adults. This combination pill is the first FDA-approved oral antidepressant that does not primarily target the monoamine neurotransmitters serotonin, dopamine, and ...
The esketamine-based nasal spray ultimately won FDA approval in 2019, delivering the depression space its first new medication in decades. Spravato also offered an option that could provide more rapid treatment than the four to six weeks selective serotonin reuptake inhibitors, depression’s go-to drugs, usually take to kick in.